progenta
Small moleculeexperimental
Telapristone, as telapristone acetate, is a synthetic, steroidal selective progesterone receptor modulator (SPRM) related to mifepristone which is under development by Repros Therapeutics for the treatment of breast cancer, endometriosis, and uterine fibroids. It was originally developed by the National Institutes of Health (NIH), and, as of 2017, is in phase II clinical trials for the aforementioned indications. In addition to its activity as an SPRM, the drug also has some antiglucocorticoid activity. — Wikipedia
Clinical trial activity
35 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
25
Phase 3
7
Phase 4
0
Earliest trial started Jul 1, 2004 (NCT01069094)
Timeline
Indications
Studied for
- Absorption · Phase 1
- Amenorrhea · Phase 1/Phase 2
- Anemia · Phase 3
- BRCA1 Protein · Phase 2
- Breast Neoplasms · Phase 2
- Drug Interactions · Phase 1
- Endometriosis · Phase 2
- Healthy Volunteers · Phase 1
- Intestinal Elimination · Phase 1
- Kidney Failure, Chronic · Phase 1/Phase 2
- Leiomyoma · Phase 3
- Liver Diseases · Phase 1
- Metabolism · Phase 1
- Mutation · Phase 2
- Pharmacokinetics · Phase 1
- Vagina · Phase 1
Mechanism of action
- Progesterone receptorMODULATOR
PGR modulator
Mixed-profile progestagen, selective progesterone receptor modulator
Chemistry & pharmacology
Loading structure…
SMILES
COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C- Mol. weight
- 505.66 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTelapristone ↗
- ChEMBLCHEMBL2105694 ↗
Also known as
- cdb4124
- cdb 4124
- cdb-4124
- cdb-4124
- cdb-4124
- proellex
- proellex
- proellex
- proellex
- progenta
- progenta
- ru-44675
- ru-44675
- telapristone acetate
- telapristone acetate
- telapristone acetate
- telapristone acetate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02811159 | Phase 2 | Jun 1, 2016 | Repros Therapeutics |
| NCT02314156 | Phase 2 | Oct 1, 2015 | National Cancer Institute (NCI), Northwestern University |
| NCT02301897 | Phase 2 | Dec 1, 2014 | Repros Therapeutics |
| NCT02323646 | Phase 2 | Dec 1, 2014 | Repros Therapeutics |
| NCT02141061 | Phase 1 | May 1, 2014 | Repros Therapeutics |
| NCT01961908 | Phase 2 | Dec 1, 2013 | Repros Therapeutics |
| NCT01962805 | Phase 1 | Oct 1, 2013 | Repros Therapeutics |
| NCT01800422 | Phase 2 | Jun 1, 2013 | Breast Cancer Research Foundation, Northwestern University, Repros Therapeutics |
| NCT01728454 | Phase 2 | Nov 1, 2012 | Repros Therapeutics |
| NCT01739621 | Phase 2 | Sep 1, 2012 | Repros Therapeutics |
| NCT01451424 | Phase 2 | Feb 1, 2012 | Repros Therapeutics |
| NCT01187043 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2010 | ICON, Repros Therapeutics |
| NCT01069120 | Phase 3 | Apr 1, 2009 | Repros Therapeutics |
| NCT00881062 | Phase 1 | Apr 1, 2009 | Repros Therapeutics |
| NCT00874302 | Phase 3 | Mar 31, 2009 | Repros Therapeutics |
| NCT00853567 | Phase 3 | Feb 1, 2009 | Repros Therapeutics |
| NCT00958412 | Phase 2 | Feb 1, 2009 | Repros Therapeutics |
| NCT00881608 | Phase 1 | Feb 1, 2009 | Repros Therapeutics |
| NCT00741273 | Phase 1 | Oct 1, 2008 | Repros Therapeutics |
| NCT00785356 | Phase 3 | Oct 1, 2008 | Repros Therapeutics |
Showing 20 of 35 trials
Page 1 / 2
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Repros Therapeutics | For profit | 34 | 33 | 3 | 2004 |
| Northwestern University | Academic/Hospital | 2 | 2 | 1 | 2013 |
| Breast Cancer Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2013 |
| ICON | For profit | 1 | 0 | 1 | 2010 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1